🎙️ JLS Podcast: William Leonard Pickard interviews Bryan Hubbard, Executive Director of the American Ibogaine Initiative

🚀 Background on Bryan Hubbard: Legal expert, policy leader, and addiction recovery advocate with deep roots in underserved communities.

Formerly: Chairman of the Kentucky Opioid Abatement Advisory Commission Special Counsel, KY Attorney General’s Office of Medicaid Fraud Commissioner, KY Department of Income Support Currently: Executive Director, American Ibogaine Initiative (via the REID Foundation) CEO, Americans for Ibogaine, a nonprofit advancing awareness and research around ibogaine's neurorestorative potential.

🧠 From Policy to Psychedelic Advocacy Hubbard’s work is fueled by a commitment to ending cycles of addiction, poverty, and systemic neglect. Became a national voice in the movement to integrate ibogaine into mainstream treatment options for opioid use disorder and traumatic brain injury.

💸 The Texas Ibogaine Initiative In partnership with former Texas Governor Rick Perry, Bryan helped secure $50 million in state funding for ibogaine research and drug development. This state-backed initiative marks one of the most significant public investments in psychedelic medicine to date — aiming to bring ibogaine through FDA trials and into legal clinical use.

🌿 What Is Ibogaine? Ibogaine is a naturally occurring psychoactive compound known for its powerful addiction-interrupting effects and potential to heal the brain. Current research points to: Disruption of opioid dependency pathways Neurorestoration after prolonged substance abuse Possible applications in PTSD, depression, and traumatic brain injury

⚖️ A New Frontier in Drug Policy Hubbard speaks on the legal and political challenges of integrating psychedelics into public health frameworks. He emphasizes: The need for state and federal collaboration Bridging science, policy, and public trust Centering underserved communities in treatment access

🔍 What’s Next American Ibogaine Initiative is preparing for clinical trials backed by state funding. Public-private partnerships are key to unlocking large-scale access. Growing bipartisan interest in psychedelics signals a major shift in U.S. drug policy.

🏆 Final Takeaways Bryan Hubbard is one of the most strategic and passionate voices working to medicalize ibogaine and transform addiction treatment in America. His blend of legal acumen, policy leadership, and heartfelt advocacy puts him at the center of a new era in mental health reform.

✨ Support this work and unlock exclusive interviews with Bryan Hubbard, biotech CEOs, ethicists, and pioneers in AI drug design on Patreon: 

https://www.patreon.com/c/thelastalchemist

🔗 Stay tuned for more updates from the frontlines of psychedelic medicine, policy, and healing.

🎙️ JLS Podcast: Leaders in Biotech Interview with Jonathan Sporn, CEO of Gilgamesh Pharmaceuticals

🚀 Company Background Founded 4 years ago with a $5,000 investment, now raised $80M in Series A funding. NIH awarded $13M in non-dilutive grants. AbbVie investment: $60M upfront, $2B in milestone payments—largest psychedelic deal in history.

🧪 Origins of Gilgamesh Pharmaceuticals Jonathan Sporn (ex-Pfizer, Harvard MD) partnered with Columbia University chemists to design novel psychedelic-inspired molecules. Initial research began in a Columbia lab, licensing certain assets while ensuring company research remained independent.

🔬 Gilgamesh’s Four Research Tracks

1️⃣ 🌀 5-HT2A Psychedelic Therapy Goal: Shorten the duration of psychedelic experiences for clinical use. Lead compound: 5-HT2A agonist with 45-minute half-life (vs. Psilocybin’s 2.5 hours). Current Status: Undergoing Phase 2 trials.

2️⃣ 🧠 Neuroplasticity Program (AbbVie Partnership) Focus: Non-hallucinogenic compounds that promote rapid antidepressant effects. Potential applications: Anxiety, depression, PTSD. Researching long-term cognitive and emotional restructuring without a "trip."

3️⃣ 💊 Ketamine/NMDA Antagonist Derivatives Goal: Oral alternative to ketamine with reduced dissociative and addictive effects. Key improvement: No opioid receptor binding (vs. Esketamine’s weak Mu opioid affinity).

4️⃣ 🌱 Ibogaine Analogs (NIH-funded) Target: Addiction treatment (opioids, meth, alcohol) with reduced cardiotoxicity risks. Developing novel compounds with Ibogaine’s efficacy but improved safety.

🔮 Broader Implications & Future of Psychedelic Medicine Neuroplasticity drugs may reshape mental health treatment beyond just symptom relief. Potential applications in cognitive enhancement, PTSD, and personality restructuring. Regulatory hurdles exist, particularly balancing psychotherapy with pharmaceutical models.

📡 Future of Drug Development & AI’s Role Gilgamesh employs AI-assisted drug discovery for compound screening. AI-generated molecules could accelerate development timelines dramatically. Maintains traditional chemistry-driven approach but open to AI advancements.

🏆 Final Takeaways Gilgamesh is positioned as the leading psychedelic biotech firm, with major funding and diverse R&D. Expect major updates in Q1 of the year. Public and private funding (NIH, AbbVie) signals mainstream biotech confidence in psychedelics.

✨ Support this work and unlock exclusive interviews with Bryan Hubbard, biotech CEOs, ethicists, and pioneers in AI drug design on Patreon: 

https://www.patreon.com/c/thelastalchemist

🔗 Stay tuned for groundbreaking developments in psychedelic medicine!